Last updated on August 2018

Combined Alternating Sunitinib and Bevacizumab (Avastin ) in Advanced Renal Cell Carcinoma (CASA)


Brief description of study

Combined sunitinib and bevacizumab in advanced renal cell carcinoma.

Detailed Study Description

This is a phase I/II trial of combined sunitinib and bevacizumab in advanced renal cell carcinoma ( CASBA) where Bevacizumab will be used only on day 29 of each 6 weeks sunitinib cycle.

Clinical Study Identifier: NCT02919371

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.